tirzepatide once weekly for the treatment of obesity journal club In an earlier analysis SURMOUNT-1 trial, (a dual glucose-dependent insulinotropic polypeptide [GIP] and glucagon-like peptide-1 [GLP-1] receptor agonist) was shown to provide substantial and sustained reductions in body weight Tirzepatide for the treatment of

In the first trial involving patients who did not use continuous positive airway pressure (CPAP) therapy, tirzepatide resulted in an average reduction of 25.3 events per hour in AHI after 52 weeks of treatment, compared to only 5.3 fewer events with a placebo

This reduces the urge to overeat and supports a calorie deficit

Schedule a Consultation at the Center for Weight Loss Surgery It can be challenging not to gain weight after stopping Ozempic, Wegogy, Mounjaro, Zepbound and other GLP-1s, but several alternatives can be more effective in the long term

This effect may be attributed to the blood glucose-lowering effect of metformin, which maintains a glucose-deprived environment unfavorable for cancer cell growth, thus increasing the efficacy of chemotherapy